2012-04-16 09:49 Isofol Medical AB Isofol Medical AB has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to start a randomized phase I/II pharmacokinetic and pharmacodynamic study of its lead candidate Modufolin® in patients with colon cancer.
2011-09-09 14:15 Aprea Stockholm, Sweden – September 9, 2011. Aprea AB today announced that it has secured SEK 20.4m (EUR 2.1m) which will allow the company to complete its planned continuation of its clinical study with APR-246 in patients with hematologic malignancies. The company also announced that Torbjörn Bjerke has been elected as a new member of the board.
2011-04-15 08:50 Isofol Medical AB Isofol Medical AB today announced that the company has enrolled its first patient in the explorative phase I/II trial, LARS2, for the treatment of rectal cancer. A total of 43 to 58 patients will receive Isofol’s novel folate-based drug Modufolin® in combination with the anti-cancer drug Alimta®.
2011-03-01 10:35 A+ Science Ulf Skough har utsetts till ny VD för A+ Science Holding AB och tillträder den 1 mars med placering i Stockholm.
2011-02-24 10:34 Isofol Medical AB Isofol Medical AB today announced that the Swedish Medical Products Agency has approved the use of Isofol Medical's newly produced vials of Modufolin® for clinical trials. This enables Isofol Medical to initiate its first clinical trial on humans, the LARS2 trial.
2010-11-08 16:00 Aprea Stockholm, Sweden – November 8, 2010. Aprea AB today announced that encouraging data from its preclinical studies with APR-246 will be presented in a poster session at the upcoming 52nd ASH (American Society of Hematology) Annual Meeting and Exposition in Orlando, FL, USA, December 4-7, 2010.
2010-09-30 11:30 Aprea Ulf Björklund has been appointed new CEO of Aprea and will start in October. Ulf Björklund is today CEO of OxyPharma. Ulf Björklund has a long experience from the pharmaceutical industry. Prior to joining OxyPharma 2002 Ulf spent more then 15 years with Pharmacia. Aprea is in the end of a Phase I study with the candidate drug APR-246 and is planning to start a Phase II study during the fall 2011.
2010-02-18 12:00 Aprea Stockholm, Sweden – February 18, 2010. Aprea, a cancer research and development company, announces today that the European Medicines Agency has adopted a positive opinion recommending Aprea’s drug candidate APR-246 for designation as orphan medicinal product to the European Commission, for the treatment of acute myeloid leukemia (AML).
2009-11-23 11:34 Sentoclone AB SentoClone AB ställer ut under IML:s (Innovativa Mindre Life Science Bolag) tak tillsammans med Abigo och CCS i monter A19:41.
2009-08-24 14:44 Sentoclone AB SentoClone har fått tillstånd från Läkemedelsverket och Etikprövningsnämnden att genomföra en randomiserad kontrollerad fas II multicenterstudie på 140 patienter med avancerat malignt melanom. Den patenterade immunologiska metod, som SentoClone AB utvecklar, kan bli den första godkända behandlingsmetoden i sitt slag på marknaden.